Loading...
Loading...
BioLineRx Ltd.
BioLineRx Ltd.. Spoken Alpha tracks BLRX's earnings calls, guidance changes, and executive accountability over time.
Spoken Alpha tracks BLRX's historical accountability: how often management beat consensus, how the stock reacted, and how guidance evolved across the cycle. The figures below are illustrative placeholder data generated for layout — they will be replaced with real deviation metrics, True Consensus values, and EODHD price reactions as those data layers land.
Beats consensus 7/10 quarters but stock falls 90% of the time
SampleWhen a company consistently beats but the stock doesn't react, consensus is usually set too low or the buy-side number is materially above sell-side. Watch for guidance walk-downs ahead of the print.
The same data on this page is available as a machine-readable feed via the Spoken Alpha API. One call returns the IR URL, recent transcripts, and accountability scores for BLRX.
curl https://api.spokenalpha.com/v1/companies/BLRX| Quarter | Actual EPS | Consensus | Surprise | 1D | 5D |
|---|---|---|---|---|---|
| Q1 FY2026 | $0.67 | $0.63 | +7.1% | -7.1% | -4.6% |
| Q4 FY2026 | $0.48 | $0.49 | -2.9% | -5.1% | -2.8% |
| Q3 FY2026 | $0.53 | $0.49 | +7.4% | -6.9% | -3.9% |
| Q2 FY2026 | $0.66 | $0.65 | +1.6% | 0.0% | +2.8% |
| Q1 FY2025 | $0.70 | $0.68 | +2.3% | -6.8% | -7.4% |
| Q4 FY2025 | $0.66 | $0.62 | +6.4% | -7.2% | -7.2% |
| Q3 FY2025 | $0.77 | $0.80 | -4.2% | -2.8% | -4.0% |
| Q2 FY2025 | $0.69 | $0.65 | +6.3% | +1.6% | -0.4% |
| Q1 FY2024 | $0.80 | $0.76 | +4.7% | -0.6% | +0.6% |
| Q4 FY2024 | $0.81 | $0.84 | -3.6% | -1.2% | -0.2% |